Harry Hollema
About
Harry Hollema is a scholar working on Oncology, Obstetrics and Gynecology and Molecular Biology.
According to data from OpenAlex, Harry Hollema has authored 229 papers receiving a total of 11.9k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Oncology, 57 papers in Obstetrics and Gynecology and 55 papers in Molecular Biology. Recurrent topics in Harry Hollema's work include Endometrial and Cervical Cancer Treatments (56 papers), Cervical Cancer and HPV Research (45 papers) and Genetic factors in colorectal cancer (36 papers). Harry Hollema is often cited by papers focused on Endometrial and Cervical Cancer Treatments (56 papers), Cervical Cancer and HPV Research (45 papers) and Genetic factors in colorectal cancer (36 papers). Harry Hollema collaborates with scholars based in Netherlands, United States and United Kingdom. Harry Hollema's co-authors include Elisabeth G.E. de Vries, Ate G.J. van der Zee, Marian J.E. Mourits, Klaske A. ten Hoor, Hans W. Nijman, Jan H. Kleibeuker, Robert M.W. Hofstra, Ate G.J. van der Zee, Geertruida H. de Bock and Steven de Jong and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Biological Chemistry.
In The Last Decade
Harry Hollema
226 papers receiving 11.6k citations
Peers
Harry Hollema
Xavier Matías‐Guiu Spain
C. Blake Gilks Canada
Russell R. Broaddus United States
Gunnar B. Kristensen Norway
Alessandro D. Santin United States
Kathleen R. Cho United States
Rex C. Bentley United States
Sarina A. Piha‐Paul United States
Samuel C. Mok United States
Masaki Mandai Japan
Citations per year, relative to Harry Hollema Harry Hollema (= 1×)
peers
Xavier Matías‐Guiu
Countries citing papers authored by Harry Hollema
Since
Specialization
Citations
This map shows the geographic impact of Harry Hollema's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harry Hollema with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harry Hollema more than expected).
Fields of papers citing papers by Harry Hollema
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Harry Hollema. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harry Hollema. The network helps show where Harry Hollema may publish in the future.
Co-authorship network of co-authors of Harry Hollema
This figure shows the co-authorship network connecting the top 25 collaborators of Harry Hollema. A scholar is included among the top collaborators of Harry Hollema based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harry Hollema. Harry Hollema is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Hollema, Harry, Marise M. Wagner, Helena C. van Doorn, et al.. (2024). High-grade serous carcinoma occurring after risk-reducing salpingo-oophorectomy in BRCA1/2 germline pathogenic variant carriers. JNCI Journal of the National Cancer Institute. 117(4). 719–727.
2.
Nimwegen, Jolien F. van, Karin van der Tuuk, S.C. Liefers, et al.. (2020). Vaginal dryness in primary Sjögren’s syndrome: a histopathological case–control study. Lara D. Veeken. 59(10). 2806–2815.
3.
Jonge, Marthe M. de, Lauren L. Ritterhouse, Cor D. de Kroon, et al.. (2019). Germline BRCA -Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity. Clinical Cancer Research. 25(24). 7517–7526.
4.
Bock, Geertruida H. de, Joanne A. de Hullu, Harry Hollema, et al.. (2018). Characteristics of Lynch Syndrome Associated Ovarian Cancer. Obstetrical & Gynecological Survey. 73(9). 527–529.
5.
Komdeur, Fenne L., Thalina M. Prins, Stephanie van de Wall, et al.. (2017). CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer. OncoImmunology. 6(9). e1338230–e1338230.
6.
Droog, Marjolein, Ekaterina Nevedomskaya, Yongsoo Kim, et al.. (2016). Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas. Cancer Research. 76(13). 3773–3784.
7.
Wouters, Maartje C.A., Fenne L. Komdeur, Hagma H. Workel, et al.. (2015). Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer. Clinical Cancer Research. 22(3). 714–724.
8.
Wouters, Maartje C.A., Marieke L. Kuijjer, Ekaterina S. Jordanova, et al.. (2014). Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer. OncoImmunology. 3(12). e962397–e962397.
9.
Oosting, Sjoukje F., Thijs H. Oude Munnink, Marjolijn N. Lub–de Hooge, et al.. (2012). Serial Zr-89-bevacizumab PET Imaging in Metastatic Renal Cell Carcinoma Patients treated with Sunitinib, or Bevacizumab Plus Interferon.. Data Archiving and Networked Services (DANS).
10.
Jong, Renske A. de, Elisabeth Pras, H. Marike Boezen, et al.. (2012). Less Gastrointestinal Toxicity After Adjuvant Radiotherapy on a Small Pelvic Field Compared to a Standard Pelvic Field in Patients With Endometrial Carcinoma. International Journal of Gynecological Cancer. 22(7). 1177–1186.
11.
Noordhuis, Maartje, Rudolf S.N. Fehrmann, G. Bea A. Wisman, et al.. (2011). Involvement of the TGF-β and β-Catenin Pathways in Pelvic Lymph Node Metastasis in Early-Stage Cervical Cancer. Clinical Cancer Research. 17(6). 1317–1330.
12.
Nagengast, Wouter B., Marjolijn N. Lub–de Hooge, Sjoukje F. Oosting, et al.. (2010). VEGF-PET Imaging Is a Noninvasive Biomarker Showing Differential Changes in the Tumor during Sunitinib Treatment. Cancer Research. 71(1). 143–153.
13.
Hooge, Marjolijn N. Lub–de, Adrienne H. Brouwers, Johan R. de Jong, et al.. (2010). VEGF-SPECT with In-111-bevacizumab in stage III/IV melanoma patients. European Journal of Nuclear Medicine and Molecular Imaging. 37.
14.
Duiker, Evelien W., Elisabeth G.E. de Vries, Devalingam Mahalingam, et al.. (2009). Enhanced Antitumor Efficacy of a DR5-Specific TRAIL Variant over Recombinant Human TRAIL in a Bioluminescent Ovarian Cancer Xenograft Model. Clinical Cancer Research. 15(6). 2048–2057.
15.
Noordhuis, Maartje, Jasper J.H. Eijsink, Klaske A. ten Hoor, et al.. (2009). Expression of Epidermal Growth Factor Receptor (EGFR) and Activated EGFR Predict Poor Response to (Chemo)radiation and Survival in Cervical Cancer. Clinical Cancer Research. 15(23). 7389–7397.
16.
Lambeck, Annechien J.A., Ninke Leffers, Baukje‐Nynke Hoogeboom, et al.. (2007). P53‐specific T cell responses in patients with malignant and benign ovarian tumors: Implications for p53 based immunotherapy. International Journal of Cancer. 121(3). 606–614.
17.
Crijns, Anne P.G., Pauline de Graeff, Dirk Geerts, et al.. (2007). MEIS and PBX homeobox proteins in ovarian cancer. European Journal of Cancer. 43(17). 2495–2505.
18.
Koornstra, Jan J., Mathilde Jalving, Jantine L. Westra, et al.. (2005). Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: Potential targets for apoptosis induction. European Journal of Cancer. 41(8). 1195–1202.
19.
Plaat, Boudewijn E. C., Winette T.A. van der Graaf, Harald J. Hoekstra, et al.. (2003). Expression of multidrug resistance proteins, P-gp, MRP1 and LRP, in soft tissue sarcomas analysed according to their histological type and grade. European Journal of Cancer. 39(7). 909–916.
20.
Franssen, E. J. F., Harry J.M. Groen, Egbert F. Smit, et al.. (1999). 99mTc-Sestamibi scanning with SDZ PSC 833 as a functional detection method for resistance modulation in patients with solid tumours.. PubMed. 19(3B). 2349–53.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Xavier Matías‐Guiu Breakdown of academic impact, for papers by C. Blake Gilks Breakdown of academic impact, for papers by Russell R. Broaddus Breakdown of academic impact, for papers by Gunnar B. Kristensen Breakdown of academic impact, for papers by Alessandro D. Santin Breakdown of academic impact, for papers by Kathleen R. Cho Breakdown of academic impact, for papers by Rex C. Bentley Breakdown of academic impact, for papers by Sarina A. Piha‐Paul Breakdown of academic impact, for papers by Samuel C. Mok Breakdown of academic impact, for papers by Masaki Mandai